Why the study?
Does the addition of mantle or mediastinal irradiation to ABVD chemotherapy increase pulmonary toxicity in patients with early-stage Hodgkin's disease?
Population
60 patients with clinical stage I to IIIA Hodgkin's disease
Comparison
Six cycles of ABVD chemotherapy plus mantle or… vs Six cycles of ABVD chemotherapy alone (n=30)
Design
RCT, enrolled onto randomized trials
Follow-up
median 30 months
Authors
Loading...
Addition of RT does not significantly increase persistent pulmonary symptoms; reinforces safety of combined-modality therapy in early-stage Hodgkin lymphoma.
Does the addition of mantle or mediastinal irradiation to ABVD chemotherapy increase pulmonary toxicity in patients with early-stage Hodgkin's disease?
ABVD chemotherapy induces acute pulmonary toxicity requiring bleomycin dose modification, and while the addition of RT further decreases FVC, it does not significantly affect functional status.
Hirsch et al. (1996) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: